Start Date
December 31, 2009
Primary Completion Date
December 31, 2010
Study Completion Date
January 31, 2011
ranibizumab
0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of Illinois at Chicago
OTHER